-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $34

Benzinga·02/18/2026 14:25:31
Listen to the news
Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and lowers the price target from $37 to $34.